BRAF inhibitors-induced panniculitis: A cutaneous side effect mimicking subcutaneous melanoma metastasis

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 2, 2015, Pages 392-393

  Chaminade, A ^a   Conte, H ^a   Jouary, T ^a   Fauconneau, A ^a   Darrigade, A S ^a   Beylot Barry, M ^a   Pham Ledard, A ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; ARTHRALGIA; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; LEG PAIN; LETTER; LYMPHOCYTIC INFILTRATION; MEDICAL HISTORY; MELANOMA METASTASIS; METASTATIC MELANOMA; PANNICULITIS; PRIORITY JOURNAL; REMISSION; SKIN BIOPSY; SKIN NODULE; VASCULITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MELANOMA; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MELANOMA; PANNICULITIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84921554225     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12397     Document Type: Letter

References (10)

1. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
2. Hauschild A, Grob J-J, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
3. Boussemart L, Routier L, Routier E, et al,. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691-1697.
4. Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D,. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357-361.
5. Novoa RA, Honda K, Koon HB, Gerstenblith MR,. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol 2012; 67: e271-e272.
6. Monfort J-B, Pagès C, Schneider P, et al,. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22: 399-401.
7. Kim GH, Levy A, Compoginis G,. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 2013; 40: 667-669.
8. Sinha R, Edmonds K, Newton-Bishop J, Gore M, Larkin J, Fearfield L,. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol 2013; 31: 320-321.
9. Villani AP, Zaharia D, Dalle S, Depaepe L, Balme B, Thomas L,. Vemurafenib-induced panniculitis. Eur J Dermatol 2013; 23: 258-260.
10. Brazzelli V, Grasso V, Borroni G,. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013; 27: 1471-1480.